Vanda Pharmaceuticals Inc Revenue Growth Rates (VNDA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vanda Pharmaceuticals Inc   (NASDAQ: VNDA)
 

VNDA's Revenue Growth by Quarter and Year

Vanda Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/VNDA/growth
https://api.csimarket.com/api/v1/companies/VNDA/fundamentals
https://api.csimarket.com/api/v1/companies/VNDA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
VNDA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 69.82
2nd Quarter June 50.53
1st Quarter March 51.72
FY 172.07

VNDAs Annual Revenue
Vanda Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 216.11 millions
Vanda Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 198.77 millions
Vanda Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 192.64 millions
Vanda Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 254.38 millions
Vanda Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 268.68 millions




VNDA Revenue third quarter 2026 Y/Y Growth Comment
Vanda Pharmaceuticals Inc achieved in the third quarter 2026, above Company average Revenue growth of 24.09% year on year, to $ 69.82 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Revenue growth. While Vanda Pharmaceuticals Inc ' s Revenue rise of 24.09% ranks overall at the positon no. 2514 in the third quarter 2026.


VNDA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 24.09 %
2nd Quarter June -3.92 %
1st Quarter March 3.36 %
FY   -

Financial Statements
Vanda Pharmaceuticals Inc 's third quarter 2026 Revenue $ 69.82 millions VNDA's Income Statement
Vanda Pharmaceuticals Inc 's third quarter 2025 Revenue $ 56.26 millions Quarterly VNDA's Income Statement


VNDA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 38.17 %
2nd Quarter June -2.3 %
1st Quarter March -9.61 %
FY (Year on Year)   -


Back to VNDA Growth rate Comparisons >> Back to VNDA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #366
Overall #2514

Revenue Y/Y Growth Statistics
High Average Low
119.16 % 17.95 % -30.81 %
(Dec 31 2015)   (Mar 31 2024)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #366
Overall #2514
Revenue Y/Y Growth Statistics
High Average Low
119.16 % 17.95 % -30.81 %
(Dec 31 2015)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Vanda Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
44.11 % 3.45 % -26.31 %
(Mar 31 2015)  


VNDA's III. Quarter Q/Q Revenue Comment
Vanda Pharmaceuticals Inc achieved in the III. Quarter 2026 above company average sequential Revenue jump of 38.17%, to $ 69.82 millions, from $50.53 millions in the second quarter.
VNDA is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 96 other companies have achieved higher Revenue quarter on quarter growth. While Vanda Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2178.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #97
Healthcare Sector #276
Overall #2178
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #97
Healthcare Sector #276
Overall #2178
Revenue Q/Q Growth Statistics
High Average Low
44.11 % 3.45 % -26.31 %
(Mar 31 2015)  


VNDA's III. Quarter Q/Q Revenue Comment
Vanda Pharmaceuticals Inc achieved in the III. Quarter 2026 above company average sequential Revenue jump of 38.17%, to $ 69.82 millions, from $50.53 millions in the second quarter.
VNDA is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 96 other companies have achieved higher Revenue quarter on quarter growth. While Vanda Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2178.


Vanda Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 229.28
Y / Y Revenue Growth (TTM) 8.11 %
Year on Year Revenue Growth Overall Ranking # 1316
Seqeuential Revenue Change (TTM) 6.28 %
Seq. Revenue Growth (TTM) Overall Ranking # 2543


Cumulative Revenue growth Comment
Although Vanda Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 17.95% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 8.11% year on year, from 6.02% in Jun 30 2026.

In the Healthcare sector 227 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 964 to 1316.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 228
Overall # 1316

Revenue TTM Y/Y Growth Statistics
High Average Low
119.16 %
 17.95 %
-30.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 366
S&P 500 # 2543
Cumulative Revenue growth Comment
Although Vanda Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 17.95% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 8.11% year on year, from 6.02% in Jun 30 2026.

In the Healthcare sector 227 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 964 to 1316.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 228
Overall # 1316

Revenue TTM Y/Y Growth Statistics
High Average Low
119.16 %
17.95 %
-30.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 366
S&P 500 # 2543




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VNDA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions
Beta Bionics Inc 30.92%$ 30.923 millions
Cadre Holdings inc 30.36%$ 30.362 millions
Krystal Biotech Inc 30.21%$ 30.206 millions
Sight Sciences Inc 29.83%$ 29.828 millions
Ge Healthcare Technologies Inc 29.41%$ 29.413 millions


About Vanda Pharmaceuticals Inc Revenue Growth Rates (VNDA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Vanda Pharmaceuticals Inc (CIK 1347178).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001347178-26-000002
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Vanda Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.